Bone Cancer SurgeryNCT07669103
Bone Cancer Surgery Prospective Database
An observational study of Bone Cancer Surgery, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
Trial summary
According to the Global Burden of Disease Report, the number of cancer patients worldwide is increasing year by year. In 2023, there were a total of 18.5 million newly confirmed cases of malignant tumors worldwide, and it is expected to grow to 30.5 million cases by 2050. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Bone Cancer Surgery
- What is being tested?
- Bone cancer surgery
- Type of treatment
- Surgery or procedure
- How many people
- 400 participants
- Where
- 1 siteChina
- Study dates
- Jul 2026to Jul 2028
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: patients undergoing elective bone cancer resection surgery
Who may be able to join
- Clinical diagnosis of bone cancer
- Scheduled to undergo elective bone cancer resection surgery
Who cannot join
- Unable to comply with follow-up
- declined participation in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
The Second Affiliated Hospital of Zhejiang University anesthesiology department
Hangzhou, Zhejiang, 310000
Min Yan, Doctor, +86 15888210247, zryanmin@zju.edu.cn
Min Yan, Doctor
About this study
Official title: Bone Cancer Surgery Prospective Database on Perioperative Characteristics and Postoperative Complications
According to the Global Burden of Disease Report, the number of cancer patients worldwide is increasing year by year. In 2023, there were a total of 18.5 million newly confirmed cases of malignant tumors worldwide, and it is expected to grow to 30.5 million cases by 2050. Among them, the number of new cases of malignant tumors of bone and articular cartilage increased by 86.4% from 1990 to 2023. Meanwhile, bone is a particularly common site for tumor metastasis, and almost half of cancer patients are at risk of developing bone metastasis. Surgical resection is the main treatment method for both primary and secondary bone cancer. For patients with bone cancer, the main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and/or nerve compression, or stabilizing pathological fractures. Surgery for bone cancer often requires extensive exploration, osteotomy, and prosthetic reconstruction, resulting in significant surgical trauma. The incidence of postoperative complications remains high. The occurrence of postoperative complications can increase patient pain, prolong hospitalization time, increase medical costs, and even endanger life. Therefore, reduction of complications and optimizing perioperative management are key issues that urgently need to be addressed in clinical practice.
Read the detailed description
At present, there is a lack of high-quality evidence-based measures for perioperative management of bone cancer. Previous studies have mainly been retrospective, with common issues such as missing variables, small sample sizes, and single disease types, making it difficult to systematically reveal perioperative pathophysiological patterns and provide reliable evidence for clinical management. Therefore, high-quality prospective studies are urgently needed.
Therefore, this study intends to conduct a prospective cohort study of patients undergoing surgery for bone cancer, establish a perioperative database, clarify the incidence of complications, explore the factors related to perioperative complications, and provide evidence-based support for improving perioperative management and patient prognosis.
- Conditions
- Bone Cancer Surgery
- Being tested
- Bone cancer surgery
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bone cancer surgeryProcedure or surgery
patients receive surgery based on the doctor's discretion and the consideration of the patients and their family
What is being measured
The primary outcome is the main question the study is designed to answer.
Complication
This includes embolic events, pulmonary complication, wound complication, acute kidney injury, death. Diagnose according to radiologic examination, sign and symptom
Measured: hospital discharge, an average of 10 days
Secondary outcomes (8)
The rate of perioperative transfusion of allogeneic blood products
This includes blood products such as plasma and platelets, erythrocytes
Measured: hospital discharge, an average of 10 days
Wound drainage volume
Accumulated postoperative wound drainage volume
Measured: hospital discharge, an average of 10 days
The coagulation function tests during the perioperative period
This includes thromboelastography result
Measured: hospital discharge, an average of 10 days
Hemoglobin levels
Hemoglobin levels during hospitalIzation
Measured: hospital discharge, an average of 10 days
6-month mortality
Measured: 6 months
1-year mortality
Measured: 1 year
2-year mortality
Measured: 2 years
3-year mortality
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2026
- Study startJul 2026 (estimated)
- Primary completionJul 2026 (estimated)
- Study completionJul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bone Cancer SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07669103
- Sponsor's protocol ID
- 2026 0873
- Status last verified
- Jun 2026
- First submitted
- 22 Jun 2026
- Last updated
- 29 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bone Cancer Surgery Prospective Database on Perioperative Characteristics and Postoperative Complications
- ClinicalTrials.gov ID
- NCT07669103
- Acronym / sponsor ID
- 2026 0873
- Conditions
- Bone Cancer Surgery
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineUniversity, hospital or other
- Study start
- Jul 2026 (estimated)
- Primary completion
- Jul 2026 (estimated)
- Study completion
- Jul 2028 (estimated)
- First posted
- 25 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
According to the Global Burden of Disease Report, the number of cancer patients worldwide is increasing year by year. In 2023, there were a total of 18.5 million newly confirmed cases of malignant tumors worldwide, and it is expected to grow to 30.5 million cases by 2050. Among them, the number of new cases of malignant tumors of bone and articular cartilage increased by 86.4% from 1990 to 2023. Meanwhile, bone is a particularly common site for tumor metastasis, and almost half of cancer patients are at risk of developing bone metastasis. Surgical resection is the main treatment method for both primary and secondary bone cancer. For patients with bone cancer, the main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and/or nerve compression, or stabilizing pathological fractures. Surgery for bone cancer often requires extensive exploration, osteotomy, and prosthetic reconstruction, resulting in significant surgical trauma. The incidence of postoperative complications remains high. The occurrence of postoperative complications can increase patient pain, prolong hospitalization time, increase medical costs, and even endanger life. Therefore, reduction of complications and optimizing perioperative management are key issues that urgently need to be addressed in clinical practice.
Detailed description
At present, there is a lack of high-quality evidence-based measures for perioperative management of bone cancer. Previous studies have mainly been retrospective, with common issues such as missing variables, small sample sizes, and single disease types, making it difficult to systematically reveal perioperative pathophysiological patterns and provide reliable evidence for clinical management. Therefore, high-quality prospective studies are urgently needed.
Therefore, this study intends to conduct a prospective cohort study of patients undergoing surgery for bone cancer, establish a perioperative database, clarify the incidence of complications, explore the factors related to perioperative complications, and provide evidence-based support for improving perioperative management and patient prognosis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- patients undergoing elective bone cancer resection surgery
Key inclusion criteria (2 listed)
- Clinical diagnosis of bone cancer
- Scheduled to undergo elective bone cancer resection surgery
Key exclusion criteria (2 listed)
- Unable to comply with follow-up
- declined participation in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bone cancer surgerypatients receive surgery based on the doctor's discretion and the consideration of the patients and their family | Procedure or surgery | – |
Primary outcome
Complication
Time frame: hospital discharge, an average of 10 days
This includes embolic events, pulmonary complication, wound complication, acute kidney injury, death. Diagnose according to radiologic examination, sign and symptom
8 secondary outcomes
The rate of perioperative transfusion of allogeneic blood products
Time frame: hospital discharge, an average of 10 days
Wound drainage volume
Time frame: hospital discharge, an average of 10 days
The coagulation function tests during the perioperative period
Time frame: hospital discharge, an average of 10 days
Hemoglobin levels
Time frame: hospital discharge, an average of 10 days
6-month mortality
Time frame: 6 months
1-year mortality
Time frame: 1 year
2-year mortality
Time frame: 2 years
3-year mortality
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2026.
Related trials for Bone Cancer Surgery
Not yet recruitingPhase 4
Remimazolam vs Propofol for Motor and Somatosensory Evoked Potentials in Spinal Tumor Surgery
Spinal Cord Neoplasms, Spinal Neoplasms
RecruitingPhase 1
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Osteosarcoma, Pulmonary Recurrence of Osteosarcoma
Not yet recruiting
Acute Normovolemic Hemodilution in Bone Cancer Surgery
Acute Normovolemic Hemodilution
Active, not recruiting
Supervised Exercise in Improving Physical Fitness Before Surgery in Patients With Resectable Bone Cancer
Malignant Bone Neoplasm
RecruitingObservational study
Biomarkers of Resiliency In Childhood Cancer Surgery
Pediatric Cancer, Neuroblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The Second Affiliated Hospital of Zhejiang University anesthesiology department
Hangzhou, China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bone Cancer Surgery, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complication (time frame: hospital discharge, an average of 10 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.